CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF397 (ImmuneEditome ID:84307)

1. Gene summary of enriched editing regions for ZNF397

check button Gene summary
Gene informationGene symbol

ZNF397

Gene ID

84307

GeneSynonymsZNF47|ZSCAN15
GeneCytomap

18q12.2

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 397|zinc finger and SCAN domain-containing protein 15|zinc finger protein 47
GeneModificationdate20230517
UniprotIDQ8NF99;Q96K65;M0R288;K7ERU5
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr18:35245641-35246162:+ENST00000330501.10ENSG00000186812.11ZNF397exonicNoRepeatchr18:35245641-35246162:+.alignment
chr18:35247696-35249710:+ENST00000589420.1ENSG00000186812.11ZNF397ncRNA_intronicL3,AluSx,AluJr,AluSp,L1ME4a,MIRchr18:35247696-35249710:+.alignment


Top

2. Tumor-specific enriched editing regions for ZNF397


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr18:35247696-35249710:+BRCAEER1.5261e-18image
ENSG00000186812.11,ZNF397BRCAEAG4.5726e-20image
chr18:35247696-35249710:+HNSCEER1.6871e-02image
ENSG00000186812.11,ZNF397HNSCEAG1.8331e-02image
chr18:35247696-35249710:+KIRPEER3.8268e-03image
ENSG00000186812.11,ZNF397KIRPEAG3.5222e-03image
chr18:35247696-35249710:+LUSCEER1.3683e-05image
ENSG00000186812.11,ZNF397LUSCEAG8.4553e-06image
chr18:35247696-35249710:+STADEER3.0839e-03image
ENSG00000186812.11,ZNF397STADEAG4.5762e-03image
chr18:35247696-35249710:+THCAEER2.0694e-04image
ENSG00000186812.11,ZNF397THCAEAG1.3586e-04image
chr18:35247696-35249710:+UCECEER1.5765e-06image
ENSG00000186812.11,ZNF397UCECEAG1.3467e-06image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000186812.11,ZNF397KICHPathEAG3.4181e-022.9089e-020.2708image
ENSG00000186812.11,ZNF397KIRCPathEAG1.7151e-021.5607e-020.1078image
chr18:35247696-35249710:+KIRCPathEER1.7126e-022.0438e-020.1033image
chr18:35247696-35249710:+THCAPathEER3.5785e-021.7881e-020.1058image
ENSG00000186812.11,ZNF397THCAPathEAG3.5118e-021.8901e-020.1048image
ENSG00000186812.11,ZNF397UCSCliEAG2.9956e-033.4716e-03-0.3841image
chr18:35247696-35249710:+UCSCliEER3.1613e-033.7646e-03-0.3810image
ENSG00000186812.11,ZNF397UVMCliEAG2.6039e-021.6145e-020.3174image
chr18:35247696-35249710:+UVMCliEER2.6039e-021.6145e-020.3174image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for ZNF397


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr18:35247696-35249710:+UVMEERENSG00000140939,NOL3-0.58941.3162e-033.0622e-04-0.4611imageNNNOL3B_cells_naiveGSVA_HALLMARK_KRAS_SIGNALING_DN
chr18:35247696-35249710:+UVMEERENSG00000100650,SRSF5-0.58661.4074e-031.6882e-04-0.4781imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_KRAS_SIGNALING_DN
chr18:35247696-35249710:+UVMEERENSG00000196123,KIAA0895L-0.57691.8568e-032.3397e-04-0.4689imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MYC_TARGETS_V2
chr18:35247696-35249710:+UVMEERENSG00000227372,TP73-AS1-0.56162.1092e-035.6316e-04-0.4428imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_KRAS_SIGNALING_DN
chr18:35247696-35249710:+UVMEERENSG00000114770,ABCC5-0.54712.4422e-031.7844e-04-0.4766imageNNABCC5T_cells_CD4_memory_restingGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr18:35247696-35249710:+UVMEERENSG00000104976,SNAPC20.55002.9415e-032.2469e-060.5802imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_UP
chr18:35247696-35249710:+UVMEERENSG00000146247,PHIP-0.54094.1259e-032.1515e-05-0.5309imageNNPHIPMacrophages_M2GSVA_HALLMARK_KRAS_SIGNALING_DN
chr18:35247696-35249710:+UVMEERENSG00000118518,RNF146-0.54124.1410e-031.6655e-04-0.4785imageNNNAMacrophages_M2GSVA_HALLMARK_PROTEIN_SECRETION
chr18:35247696-35249710:+UVMEERENSG00000223705,NSUN5P1-0.53344.5036e-033.4270e-04-0.4578imageNNNAT_cells_follicular_helperGSVA_HALLMARK_KRAS_SIGNALING_DN
chr18:35247696-35249710:+UVMEERENSG00000167615,LENG8-0.53634.6498e-031.3954e-03-0.4133imageNNLENG8NK_cells_restingGSVA_HALLMARK_KRAS_SIGNALING_DN

More results



Top

4. Enriched editing regions and immune related splicing for ZNF397


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr18:35247696-35249710:+
UCECEERA5ENSG00000173432.6chr1118266883:18266978:18266259:18266296:18266259:18266443-0.30528.6133e-033.1992e-07-0.4351imageNNSAA1B_cells_naiveGSVA_HALLMARK_UV_RESPONSE_DN
ENSG00000186812.11,ZNF397
UCECEAGA5ENSG00000173432.6chr1118266883:18266978:18266259:18266296:18266259:18266443-0.30718.0040e-032.7371e-07-0.4373imageNELAVL1;FUS;HNRNPL;METTL3;SRSF1;SRSF3;TAF15;TROVE2SAA1B_cells_naiveGSVA_HALLMARK_UV_RESPONSE_DN
chr18:35247696-35249710:+
UVMEERIRENSG00000167747.9chr1950797703:50798958:50799271:50799357-0.52711.2325e-022.3279e-05-0.5462imageNNNAMast_cells_activatedGSVA_HALLMARK_KRAS_SIGNALING_DN
chr18:35247696-35249710:+
UVMEERMEXENSG00000180902.12chr2241744708:241744877:241748864:241750294:241754630:241754746:241755044:2417552100.47032.6732e-021.4266e-030.4271imageNNNAMast_cells_activatedGSVA_HALLMARK_KRAS_SIGNALING_DN
chr18:35247696-35249710:+
UVMEERA3ENSG00000025796.9chr6107904628:107904716:107902843:107902994:107902843:107902998-0.56313.0160e-043.0791e-05-0.5264imageNNNANK_cells_restingGSVA_HALLMARK_KRAS_SIGNALING_DN
chr18:35247696-35249710:+
UVMEERIRENSG00000138668.14chr482353833:82355001:82355303:82355401-0.46683.9706e-026.1990e-06-0.5911imageNNNAMacrophages_M2GSVA_HALLMARK_KRAS_SIGNALING_DN
chr18:35247696-35249710:+
UVMEERIRENSG00000143303.7chr1156731990:156732115:156732280:156732473-0.51813.7919e-022.9594e-04-0.4621imageNNNAB_cells_naiveGSVA_HALLMARK_KRAS_SIGNALING_DN
ENSG00000186812.11,ZNF397
UVMEAGIRENSG00000165782.6chr1420459627:20460845:20461162:20461465-0.51183.9868e-021.9528e-03-0.4086imageNAIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RC3H1;RNF219;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184NAMast_cells_activatedGSVA_HALLMARK_KRAS_SIGNALING_DN
ENSG00000186812.11,ZNF397
UVMEAGIRENSG00000185522.4chr11555304:556588:556834:557097-0.49991.7063e-024.8313e-04-0.5042imageNADAR;BCCIP;BUD13;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP3;ILF3;LIN28B;LSM11;NONO;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NANK_cells_restingGSVA_HALLMARK_KRAS_SIGNALING_DN
chr18:35247696-35249710:+
UVMEERIRENSG00000165782.6chr1420459627:20460845:20461183:20461612-0.52592.4713e-022.6410e-04-0.4692imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_KRAS_SIGNALING_DN

More results



Top

5. Enriched editing regions and immune infiltration for ZNF397


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr18:35247696-35249710:+ACCEERNeutrophils1.9107e-020.2701image
ENSG00000186812.11,ZNF397ACCEAGNeutrophils1.9395e-020.2695image
chr18:35247696-35249710:+BLCAEERT_cells_regulatory_(Tregs)1.1659e-03-0.1686image
ENSG00000186812.11,ZNF397BLCAEAGT_cells_regulatory_(Tregs)2.4351e-03-0.1576image
chr18:35247696-35249710:+BRCAEERMacrophages_M02.0537e-030.0942image
ENSG00000186812.11,ZNF397BRCAEAGMacrophages_M03.1201e-030.0903image
chr18:35247696-35249710:+CESCEERT_cells_CD4_memory_activated4.9065e-020.1165image
ENSG00000186812.11,ZNF397CESCEAGT_cells_CD4_memory_activated4.7740e-020.1172image
chr18:35247696-35249710:+CHOLEERT_cells_CD4_memory_activated2.2809e-020.3894image
ENSG00000186812.11,ZNF397CHOLEAGT_cells_CD4_memory_activated2.2809e-020.3894image
chr18:35247696-35249710:+COADEERT_cells_follicular_helper2.2173e-030.1999image
ENSG00000186812.11,ZNF397COADEAGT_cells_follicular_helper2.8064e-030.1954image
chr18:35247696-35249710:+DLBCEERDendritic_cells_resting2.7263e-020.3256image
ENSG00000186812.11,ZNF397DLBCEAGDendritic_cells_resting2.6482e-020.3271image
chr18:35247696-35249710:+ESCAEERT_cells_gamma_delta6.1625e-030.2177image
ENSG00000186812.11,ZNF397ESCAEAGT_cells_regulatory_(Tregs)2.2639e-02-0.1819image
chr18:35247696-35249710:+GBMEERDendritic_cells_activated1.3186e-020.1981image
ENSG00000186812.11,ZNF397GBMEAGDendritic_cells_activated2.6373e-020.1778image
chr18:35247696-35249710:+HNSCEERNK_cells_resting6.3855e-040.1960image
ENSG00000186812.11,ZNF397HNSCEAGNK_cells_resting7.4615e-040.1930image
ENSG00000186812.11,ZNF397KICHEAGT_cells_CD4_memory_activated7.0443e-030.3312image
chr18:35247696-35249710:+KIRCEERT_cells_gamma_delta5.4791e-030.1449image
ENSG00000186812.11,ZNF397KIRCEAGT_cells_gamma_delta6.7628e-030.1413image
chr18:35247696-35249710:+KIRPEERB_cells_naive8.7568e-030.1614image
ENSG00000186812.11,ZNF397KIRPEAGB_cells_naive8.7110e-030.1615image
chr18:35245641-35246162:+LGGEERDendritic_cells_resting8.1042e-070.4903image
chr18:35247696-35249710:+LGGEERNK_cells_activated1.7113e-03-0.1363image
ENSG00000186812.11,ZNF397LGGEAGNK_cells_activated7.6355e-04-0.1462image
chr18:35247696-35249710:+LUADEERNeutrophils2.0042e-030.1451image
ENSG00000186812.11,ZNF397LUADEAGNeutrophils1.4190e-030.1495image
chr18:35247696-35249710:+LUSCEERDendritic_cells_activated2.9492e-020.1037image
ENSG00000186812.11,ZNF397LUSCEAGDendritic_cells_activated2.8385e-020.1044image
chr18:35247696-35249710:+MESOEERT_cells_CD82.1371e-020.2603image
ENSG00000186812.11,ZNF397MESOEAGT_cells_CD81.9418e-020.2642image
chr18:35245641-35246162:+OVEERT_cells_gamma_delta1.5601e-020.4115image
chr18:35247696-35249710:+OVEERMacrophages_M13.3731e-030.1731image
ENSG00000186812.11,ZNF397OVEAGMacrophages_M15.2292e-030.1650image
chr18:35247696-35249710:+PAADEERMacrophages_M04.8723e-030.2222image
ENSG00000186812.11,ZNF397PAADEAGMacrophages_M03.7103e-030.2282image
chr18:35247696-35249710:+PCPGEERMacrophages_M09.2891e-040.2434image
ENSG00000186812.11,ZNF397PCPGEAGMacrophages_M09.2397e-040.2435image
chr18:35247696-35249710:+PRADEERPlasma_cells3.3543e-03-0.1316image
ENSG00000186812.11,ZNF397PRADEAGPlasma_cells4.5492e-03-0.1273image
chr18:35247696-35249710:+SARCEERNeutrophils2.8737e-030.1961image
ENSG00000186812.11,ZNF397SARCEAGT_cells_CD4_memory_activated9.2666e-030.1716image
chr18:35245641-35246162:+STADEERT_cells_CD85.3529e-030.3773image
chr18:35247696-35249710:+STADEERB_cells_naive2.1855e-03-0.1656image
ENSG00000186812.11,ZNF397STADEAGB_cells_naive6.2873e-03-0.1473image
chr18:35247696-35249710:+TGCTEERMast_cells_resting4.7619e-020.1594image
ENSG00000186812.11,ZNF397TGCTEAGMast_cells_resting4.1281e-020.1641image
chr18:35247696-35249710:+THCAEERNeutrophils1.4700e-02-0.1087image
ENSG00000186812.11,ZNF397THCAEAGNeutrophils9.4092e-03-0.1157image
chr18:35247696-35249710:+THYMEERB_cells_naive1.3010e-040.3450image
ENSG00000186812.11,ZNF397THYMEAGB_cells_naive8.4081e-040.3033image
chr18:35247696-35249710:+UCECEERMast_cells_activated3.1242e-02-0.1643image
ENSG00000186812.11,ZNF397UCECEAGMast_cells_activated3.0393e-02-0.1651image


Top

6. Enriched editing regions and immune gene sets for ZNF397


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr18:35247696-35249710:+STADEER1.2906e-02image1.0843e-020.1380image
ENSG00000186812.11,ZNF397STADEAG1.7991e-02image1.0186e-020.1386image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr18:35247696-35249710:+BLCAEER5.6695e-030.14392.0666e-020.12065.9740e-030.14317.2186e-030.1398image
ENSG00000186812.11,ZNF397BLCAEAG7.4566e-030.13932.4520e-020.11721.2553e-020.13001.1137e-020.1322image
ENSG00000186812.11,ZNF397STADEAG3.8823e-040.19052.2772e-030.16424.4826e-040.18851.2973e-050.2330image
chr18:35247696-35249710:+STADEER3.6875e-050.22184.4752e-040.18947.3097e-050.21346.7530e-060.2414image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000186812.11,ZNF397ACCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG1.5504e-020.2786image
chr18:35247696-35249710:+ACCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER1.2321e-020.2877image
chr18:35247696-35249710:+BLCAGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER1.8075e-040.1940image
ENSG00000186812.11,ZNF397BLCAGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG2.6244e-040.1892image
ENSG00000186812.11,ZNF397BRCAGSVA_HALLMARK_MTORC1_SIGNALINGEAG1.7929e-050.1308image
chr18:35245641-35246162:+BRCAGSVA_HALLMARK_MITOTIC_SPINDLEEER6.5561e-03-0.2650image
chr18:35247696-35249710:+BRCAGSVA_HALLMARK_MTORC1_SIGNALINGEER1.1829e-040.1175image
ENSG00000186812.11,ZNF397CESCGSVA_HALLMARK_COMPLEMENTEAG1.7613e-040.2200image
chr18:35247696-35249710:+CESCGSVA_HALLMARK_COMPLEMENTEER1.7800e-040.2199image
ENSG00000186812.11,ZNF397CHOLGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG4.4669e-020.3465image
chr18:35247696-35249710:+CHOLGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER4.4669e-020.3465image
ENSG00000186812.11,ZNF397COADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG4.0814e-020.1344image
ENSG00000186812.11,ZNF397DLBCGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.1734e-020.3685image
chr18:35247696-35249710:+DLBCGSVA_HALLMARK_FATTY_ACID_METABOLISMEER1.1987e-020.3675image
chr18:35247696-35249710:+ESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEER5.6080e-03-0.2201image
ENSG00000186812.11,ZNF397ESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEAG3.0884e-03-0.2347image
ENSG00000186812.11,ZNF397GBMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.3804e-020.1968image
chr18:35247696-35249710:+GBMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.1241e-020.2025image
chr18:35247696-35249710:+HNSCGSVA_HALLMARK_MYC_TARGETS_V1EER1.0918e-020.1468image
ENSG00000186812.11,ZNF397HNSCGSVA_HALLMARK_MYC_TARGETS_V1EAG8.3668e-030.1515image
ENSG00000186812.11,ZNF397KICHGSVA_HALLMARK_PEROXISOMEEAG1.7767e-02-0.2932image
chr18:35247696-35249710:+KIRCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.8263e-060.2420image
ENSG00000186812.11,ZNF397KIRCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.7056e-060.2471image
chr18:35247696-35249710:+KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.8182e-050.2609image
ENSG00000186812.11,ZNF397KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.8459e-050.2608image
chr18:35245641-35246162:+LAMLGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.8131e-020.4152image
chr18:35247696-35249710:+LAMLGSVA_HALLMARK_UV_RESPONSE_UPEER7.0126e-030.2642image
ENSG00000186812.11,ZNF397LAMLGSVA_HALLMARK_UV_RESPONSE_UPEAG2.9973e-040.3340image
chr18:35245641-35246162:+LGGGSVA_HALLMARK_MYOGENESISEER8.3570e-040.3442image
chr18:35247696-35249710:+LGGGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER3.9045e-060.1995image
ENSG00000186812.11,ZNF397LGGGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG2.6270e-070.2220image
ENSG00000186812.11,ZNF397LIHCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG2.9979e-030.1672image
chr18:35247696-35249710:+LIHCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER3.0092e-030.1672image
ENSG00000186812.11,ZNF397LUADGSVA_HALLMARK_GLYCOLYSISEAG2.8716e-040.1696image
chr18:35247696-35249710:+LUADGSVA_HALLMARK_GLYCOLYSISEER1.7096e-030.1473image
chr18:35247696-35249710:+LUSCGSVA_HALLMARK_GLYCOLYSISEER2.0049e-030.1467image
ENSG00000186812.11,ZNF397LUSCGSVA_HALLMARK_GLYCOLYSISEAG1.8919e-030.1475image
ENSG00000186812.11,ZNF397MESOGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG1.5737e-020.2726image
chr18:35247696-35249710:+MESOGSVA_HALLMARK_IL2_STAT5_SIGNALINGEER1.5873e-020.2723image
ENSG00000186812.11,ZNF397OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG6.3282e-06-0.2639image
chr18:35247696-35249710:+OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER7.9197e-06-0.2612image
chr18:35245641-35246162:+OVGSVA_HALLMARK_SPERMATOGENESISEER2.1392e-030.5084image
chr18:35247696-35249710:+PAADGSVA_HALLMARK_GLYCOLYSISEER2.5374e-040.2863image
ENSG00000186812.11,ZNF397PAADGSVA_HALLMARK_GLYCOLYSISEAG2.0198e-040.2898image
ENSG00000186812.11,ZNF397PCPGGSVA_HALLMARK_HEME_METABOLISMEAG1.0974e-020.1882image
chr18:35247696-35249710:+PCPGGSVA_HALLMARK_HEME_METABOLISMEER1.0493e-020.1893image
ENSG00000186812.11,ZNF397PRADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG7.1908e-03-0.1207image
chr18:35247696-35249710:+PRADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.0087e-02-0.1156image
ENSG00000186812.11,ZNF397READGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG2.4874e-030.3466image
chr18:35247696-35249710:+READGSVA_HALLMARK_FATTY_ACID_METABOLISMEER2.4874e-030.3466image
chr18:35247696-35249710:+SARCGSVA_HALLMARK_GLYCOLYSISEER4.9369e-050.2648image
ENSG00000186812.11,ZNF397SARCGSVA_HALLMARK_GLYCOLYSISEAG9.2335e-050.2555image
ENSG00000186812.11,ZNF397SKCMGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.8179e-060.2343image
chr18:35247696-35249710:+SKCMGSVA_HALLMARK_FATTY_ACID_METABOLISMEER1.5852e-060.2356image
chr18:35245641-35246162:+STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.5961e-020.3058image
chr18:35247696-35249710:+STADGSVA_HALLMARK_GLYCOLYSISEER8.3471e-110.3427image
ENSG00000186812.11,ZNF397STADGSVA_HALLMARK_GLYCOLYSISEAG1.0799e-100.3394image
chr18:35247696-35249710:+THCAGSVA_HALLMARK_GLYCOLYSISEER4.0815e-040.1570image
ENSG00000186812.11,ZNF397THCAGSVA_HALLMARK_GLYCOLYSISEAG3.8092e-040.1578image
chr18:35247696-35249710:+THYMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.2214e-06-0.4294image
ENSG00000186812.11,ZNF397THYMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG6.2303e-07-0.4399image
ENSG00000186812.11,ZNF397UCECGSVA_HALLMARK_UV_RESPONSE_UPEAG1.6174e-020.1832image
chr18:35247696-35249710:+UCECGSVA_HALLMARK_UV_RESPONSE_UPEER1.6245e-020.1830image
chr18:35247696-35249710:+UCSGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER9.7165e-030.3427image
ENSG00000186812.11,ZNF397UCSGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG8.9436e-030.3463image
chr18:35247696-35249710:+UVMGSVA_HALLMARK_APICAL_JUNCTIONEER1.5131e-040.4812image
ENSG00000186812.11,ZNF397UVMGSVA_HALLMARK_APICAL_JUNCTIONEAG1.5131e-040.4812image


Top

7. Enriched editing regions and drugs for ZNF397


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr18:35247696-35249710:+ACCAICAREER1.7499e-02-0.2737image
ENSG00000186812.11,ZNF397ACCAICAREAG2.2004e-02-0.2642image
ENSG00000186812.11,ZNF397BLCAEHT.1864EAG1.3442e-040.1977image
chr18:35247696-35249710:+BLCAEHT.1864EER4.3869e-050.2113image
chr18:35245641-35246162:+BRCADMOGEER3.0238e-030.2881image
chr18:35247696-35249710:+BRCAGW843682XEER5.4448e-040.1056image
ENSG00000186812.11,ZNF397BRCACHIR.99021EAG3.4949e-040.1092image
ENSG00000186812.11,ZNF397CESCCI.1040EAG6.7459e-05-0.2334image
chr18:35247696-35249710:+CESCCI.1040EER7.2011e-05-0.2325image
ENSG00000186812.11,ZNF397CHOLCGP.60474EAG8.5475e-040.5452image
chr18:35247696-35249710:+CHOLCGP.60474EER8.5475e-040.5452image
chr18:35247696-35249710:+DLBCAZD8055EER3.6585e-04-0.5031image
ENSG00000186812.11,ZNF397DLBCAZD8055EAG3.4403e-04-0.5050image
chr18:35247696-35249710:+ESCAErlotinibEER1.4016e-03-0.2528image
ENSG00000186812.11,ZNF397ESCAErlotinibEAG6.4224e-04-0.2695image
chr18:35247696-35249710:+GBMAG.014699EER6.6623e-030.2164image
ENSG00000186812.11,ZNF397GBMAG.014699EAG4.8466e-030.2245image
ENSG00000186812.11,ZNF397HNSCCI.1040EAG5.1339e-03-0.1606image
chr18:35247696-35249710:+HNSCCI.1040EER5.2296e-03-0.1609image
ENSG00000186812.11,ZNF397KICHAKT.inhibitor.VIIIEAG1.0802e-040.4618image
ENSG00000186812.11,ZNF397KIRCBAY.61.3606EAG2.7691e-050.2172image
chr18:35247696-35249710:+KIRCBAY.61.3606EER4.2467e-050.2123image
chr18:35247696-35249710:+KIRPGSK.650394EER2.2040e-050.2584image
ENSG00000186812.11,ZNF397KIRPGSK.650394EAG2.2224e-050.2583image
chr18:35247696-35249710:+LAMLAZ628EER1.0816e-02-0.2502image
ENSG00000186812.11,ZNF397LAMLAZ628EAG1.4738e-03-0.2957image
chr18:35245641-35246162:+LAMLLenalidomideEER2.2443e-030.5208image
ENSG00000186812.11,ZNF397LGGEpothilone.BEAG4.0263e-080.2363image
chr18:35245641-35246162:+LGGGNF.2EER2.2112e-03-0.3169image
chr18:35247696-35249710:+LGGEpothilone.BEER5.6248e-080.2338image
chr18:35247696-35249710:+LIHCAICAREER3.7096e-03-0.1636image
ENSG00000186812.11,ZNF397LIHCAICAREAG3.6658e-03-0.1638image
ENSG00000186812.11,ZNF397LUADCCT018159EAG2.8736e-02-0.1028image
chr18:35247696-35249710:+LUADCCT018159EER4.3638e-02-0.0950image
chr18:35247696-35249710:+LUSCATRAEER2.2635e-030.1450image
ENSG00000186812.11,ZNF397LUSCMethotrexateEAG2.0128e-030.1474image
chr18:35247696-35249710:+MESOAZD6244EER3.8422e-04-0.3921image
ENSG00000186812.11,ZNF397MESOAZD6244EAG2.1305e-04-0.4075image
chr18:35245641-35246162:+OVMG.132EER3.8938e-05-0.6445image
chr18:35247696-35249710:+OVBexaroteneEER4.6294e-060.2676image
ENSG00000186812.11,ZNF397OVBexaroteneEAG9.5818e-070.2854image
ENSG00000186812.11,ZNF397PAADAxitinibEAG6.3877e-030.2161image
chr18:35247696-35249710:+PAADAxitinibEER6.3648e-030.2169image
ENSG00000186812.11,ZNF397PCPGEHT.1864EAG1.1020e-030.2400image
chr18:35247696-35249710:+PCPGEHT.1864EER1.0389e-030.2412image
ENSG00000186812.11,ZNF397PRADEpothilone.BEAG9.8534e-030.1159image
chr18:35247696-35249710:+PRADDocetaxelEER3.8329e-030.1299image
ENSG00000186812.11,ZNF397READABT.263EAG6.1451e-040.3915image
chr18:35247696-35249710:+READABT.263EER6.1451e-040.3915image
chr18:35247696-35249710:+SARCEHT.1864EER1.0709e-040.2532image
ENSG00000186812.11,ZNF397SARCEHT.1864EAG7.2604e-050.2591image
ENSG00000186812.11,ZNF397SKCMLapatinibEAG3.5297e-040.1769image
chr18:35247696-35249710:+SKCMGefitinibEER4.0870e-040.1752image
chr18:35247696-35249710:+STADAG.014699EER3.7587e-060.2478image
ENSG00000186812.11,ZNF397STADBMS.708163EAG4.8288e-060.2440image
ENSG00000186812.11,ZNF397TGCTElesclomolEAG4.0328e-030.2297image
chr18:35247696-35249710:+TGCTElesclomolEER3.8781e-030.2307image
ENSG00000186812.11,ZNF397THCAATRAEAG4.5080e-030.1266image
chr18:35247696-35249710:+THCAATRAEER4.5836e-030.1263image
chr18:35247696-35249710:+THYMBexaroteneEER1.9569e-060.4219image
ENSG00000186812.11,ZNF397THYMBexaroteneEAG1.1197e-060.4308image
chr18:35247696-35249710:+UCECCCT007093EER1.9344e-030.2348image
ENSG00000186812.11,ZNF397UCECCCT007093EAG1.6914e-030.2377image
ENSG00000186812.11,ZNF397UCSAZ628EAG1.5780e-03-0.4126image
chr18:35247696-35249710:+UCSAZ628EER1.6451e-03-0.4111image
ENSG00000186812.11,ZNF397UVMBexaroteneEAG1.6436e-04-0.4789image
chr18:35247696-35249710:+UVMBexaroteneEER1.6436e-04-0.4789image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType